Literature DB >> 4323972

Treatment of ocular myasthenia with corticotrophin.

F B Gibberd, F Navab, C L Smith.   

Abstract

Nine patients with severe myasthenia gravis, including ocular symptoms, who did not respond to anticholinesterase therapy were given prolonged courses of corticotrophin. In all patients except one there was an initial deterioration, sometimes necessitating assisted respiration, followed by a marked improvement which persisted for many weeks and occasionally months. It is concluded that corticotrophin should be continued for at least two weeks as the onset of the remission might be delayed. Repeated courses or small maintenance doses prolonged the remission. Fluid retention and hypokalaemia were common unwanted effects but necessitated stopping the treatment in only one patient.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4323972      PMCID: PMC493678          DOI: 10.1136/jnnp.34.1.11

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  13 in total

1.  CORTICOTROPIN IN TREATMENT OF OCULAR MYASTHENIA; A CONTROLLED CLINICAL TRIAL.

Authors:  F W MOUNT
Journal:  Arch Neurol       Date:  1964-08

2.  REACTIVITY OF MYASTHENIA GRAVIS SERUM GAMMA-GLOBULIN WITH SKELETAL MUSCLE AND THYMUS DEMONSTRATED BY IMMUNOFLUORESCENCE.

Authors:  H VAN DER GELD; T E FELTKAMP; H J OOSTERHUIS
Journal:  Proc Soc Exp Biol Med       Date:  1964-03

3.  MYASTHENIA GRAVIS AND AUTO-IMMUNE DISEASE: REVIEW OF THE LITERATURE INCLUDING A CASE REPORT OF THE COEXISTENCE OF MYASTHENIA AND SYSTEMIC LUPUS ERYTHEMATOSUS.

Authors:  T E PIEMME
Journal:  Ann Intern Med       Date:  1964-01       Impact factor: 25.391

4.  ACTH FOR OCULAR MYASTHENIA.

Authors:  F W MOUNT
Journal:  JAMA       Date:  1964-07-06       Impact factor: 56.272

5.  The autoimmune response in myasthenia gravis.

Authors:  R G WHITE; A H MARSHALL
Journal:  Lancet       Date:  1962-07-21       Impact factor: 79.321

6.  Clinical-evaluation of ACTH and cortisone in myasthenia gravis.

Authors:  C H MILLIKAN; L M EATON
Journal:  Neurology       Date:  1951 Mar-Apr       Impact factor: 9.910

7.  Studies in myasthenia gravis. Short-term massive corticotropin therapy.

Authors:  K E Osserman; G Genkins
Journal:  JAMA       Date:  1966-11-14       Impact factor: 56.272

8.  Corticotropin in generalized myasthenia gravis. Effect of short, intensive courses.

Authors:  D Grob; T Namba
Journal:  JAMA       Date:  1966-11-14       Impact factor: 56.272

9.  Treatment of severe myasthenia gravis with large doses of ACTH.

Authors:  G von Reis; A Liljestrand; G Matell
Journal:  Ann N Y Acad Sci       Date:  1966-01-26       Impact factor: 5.691

10.  Treatment of myasthenia gravis with adrenocorticotropic hormone (ACTH): massive short-term and maintenance treatment.

Authors:  C A Cape; R A Utterback
Journal:  J Neurol Neurosurg Psychiatry       Date:  1969-08       Impact factor: 10.154

View more
  2 in total

1.  Benefit from adrenocorticotrophin in myasthenia gravis.

Authors:  L A Liversedge; G M Yuill; I M Wilkinson; J A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-04       Impact factor: 10.154

2.  Myasthenia gravis, ulcerative colitis and lichen planus.

Authors:  T N Miller
Journal:  Proc R Soc Med       Date:  1971-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.